Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Open access
Stockley, Tracy L., Oza, Amit M., Berman, Hal K., Leighl, Natasha B., Knox, Jennifer J., Shepherd, Frances A., Chen, Eric X., Krzyzanowska, Monika K., Dhani, Neesha, Joshua, Anthony M., Tsao, Ming-Sound, Serra, Stefano, Clarke, Blaise, Roehrl, Michael H., Zhang, Tong, Sukhai, Mahadeo A., Califaretti, Nadia, Trinkaus, Mateya, Shaw, Patricia, van der Kwast, Theodorus, Wang, Lisa, Virtanen, Carl, Kim, Raymond H., Razak, Albiruni R. A., Hansen, Aaron R., Yu, Celeste, Pugh, Trevor J., Kamel-Reid, Suzanne, Siu, Lillian L., Bedard, Philippe L.·2016·Genome Medicine

Abstract

BACKGROUND: The clinical utility of molecular profiling of tumor tissue to guide treatment of patients with advanced solid tumors is unknown. Our objectives were to evaluate the frequency of genomic alterations, clinical "actionability" of somatic variants, enrollment in mutation-targeted or other clinical trials, and outcome of molecular profiling for advanced solid tumor patients at the Princess Margaret Cancer Centre (PM). METHODS: Patients with advanced solid tumors aged ≥18 years, good performance status, and archival tumor tissue available were prospectively consented. DNA from archival formalin-fixed paraffin-embedded tumor tissue was tested using a MALDI-TOF MS hotspot panel or a targeted next generation sequencing (NGS) panel. Somatic variants were classified according to clinical actionability and an annotated report included in the electronic medical record. Oncologists were provided with summary tables of their patients' molecular profiling results and available mutation-specific clinical trials. Enrolment in genotype-matched versus genotype-unmatched clinical trials following release of profiling results and response by RECIST v1.1 criteria were evaluated. RESULTS: From March 2012 to July 2014, 1893 patients were enrolled and 1640 tested. After a median follow-up of 18 months, 245 patients (15 %) who were tested were subsequently treated on 277 therapeutic clinical trials, including 84 patients (5 %) on 89 genotype-matched trials. The overall response rate was higher in patients treated on genotype-matched trials (19 %) compared with genotype-unmatched trials (9 %; p < 0.026). In a multi-variable model, trial matching by genotype (p = 0.021) and female gender (p = 0.034) were the only factors associated with increased likelihood of treatment response. CONCLUSIONS: Few advanced solid tumor patients enrolled in a prospective institutional molecular profiling trial were treated subsequently on genotype-matched therapeutic trials. In this non-randomized comparison, genotype-enrichment of early phase clinical trials was associated with an increased objective tumor response rate. TRIAL REGISTRATION: NCT01505400 (date of registration 4 January 2012).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-016-0364-2

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 276

Metadata

Authors
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., Tsao, M.-S., Serra, S., Clarke, B., Roehrl, M. H., Zhang, T., Sukhai, M. A., Califaretti, N., Trinkaus, M., Shaw, P., van der Kwast, T., Wang, L., Virtanen, C., Kim, R. H., Razak, A. R. A., Hansen, A. R., Yu, C., Pugh, T. J., Kamel-Reid, S., Siu, L. L., & Bedard, P. L.
Venue
Genome Medicine
Published
2016-10-25
Volume
8
Issue
1
Pages
109-109
ISSN
1756-994X (ISSN-L)
OpenAlex
W2538407824
Cited by
276
References
28
FWCI
12.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. https://app.cochat.ai/papers/10.1186/s13073-016-0364-2
The paper
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., Tsao, M.-S., Serra, S., Clarke, B., Roehrl, M. H., Zhang, T., Sukhai, M. A., Califaretti, N., Trinkaus, M., Shaw, P., . . . Bedard, P. L. (2016). Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine. https://doi.org/10.1186/s13073-016-0364-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.